364 related articles for article (PubMed ID: 23475757)
1. Histone deacetylase inhibitors in the treatment for multiple myeloma.
Hideshima T; Anderson KC
Int J Hematol; 2013 Mar; 97(3):324-32. PubMed ID: 23475757
[TBL] [Abstract][Full Text] [Related]
2. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma.
Richardson PG; Mitsiades CS; Laubach JP; Hajek R; Spicka I; Dimopoulos MA; Moreau P; Siegel DS; Jagannath S; Anderson KC
Leuk Res; 2013 Jul; 37(7):829-37. PubMed ID: 23582718
[TBL] [Abstract][Full Text] [Related]
3. The role of histone deacetylases (HDACs) in human cancer.
Ropero S; Esteller M
Mol Oncol; 2007 Jun; 1(1):19-25. PubMed ID: 19383284
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma Therapy.
Gkotzamanidou M; Terpou E; Kentepozidis N; Terpos E
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638744
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC.
Mithraprabhu S; Khong T; Jones SS; Spencer A
Br J Haematol; 2013 Aug; 162(4):559-62. PubMed ID: 23692150
[No Abstract] [Full Text] [Related]
6. The antiparasitic clioquinol induces apoptosis in leukemia and myeloma cells by inhibiting histone deacetylase activity.
Cao B; Li J; Zhu J; Shen M; Han K; Zhang Z; Yu Y; Wang Y; Wu D; Chen S; Sun A; Tang X; Zhao Y; Qiao C; Hou T; Mao X
J Biol Chem; 2013 Nov; 288(47):34181-34189. PubMed ID: 24114842
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma.
Kikuchi J; Wada T; Shimizu R; Izumi T; Akutsu M; Mitsunaga K; Noborio-Hatano K; Nobuyoshi M; Ozawa K; Kano Y; Furukawa Y
Blood; 2010 Jul; 116(3):406-17. PubMed ID: 20351311
[TBL] [Abstract][Full Text] [Related]
8. The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.
Kikuchi J; Yamada S; Koyama D; Wada T; Nobuyoshi M; Izumi T; Akutsu M; Kano Y; Furukawa Y
J Biol Chem; 2013 Aug; 288(35):25593-25602. PubMed ID: 23878197
[TBL] [Abstract][Full Text] [Related]
9. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors in multiple myeloma: from bench to bedside.
Harada T; Hideshima T; Anderson KC
Int J Hematol; 2016 Sep; 104(3):300-9. PubMed ID: 27099225
[TBL] [Abstract][Full Text] [Related]
11. Histones and lung cancer: Are the histone deacetylases a promising therapeutic target?
Petta V; Gkiozos I; Strimpakos A; Syrigos K
Cancer Chemother Pharmacol; 2013 Nov; 72(5):935-52. PubMed ID: 24036844
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Expression Signature of Histone Deacetylases (HDACs) in Mesenchymal Stem Cells from Multiple Myeloma and Normal Donors.
Ahmadvand M; Noruzinia M; Soleimani M; Abroun S
Asian Pac J Cancer Prev; 2016; 17(7):3605-10. PubMed ID: 27510016
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
Ramaiah MJ; Tangutur AD; Manyam RR
Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.
Minami J; Suzuki R; Mazitschek R; Gorgun G; Ghosh B; Cirstea D; Hu Y; Mimura N; Ohguchi H; Cottini F; Jakubikova J; Munshi NC; Haggarty SJ; Richardson PG; Hideshima T; Anderson KC
Leukemia; 2014 Mar; 28(3):680-9. PubMed ID: 23913134
[TBL] [Abstract][Full Text] [Related]
15. HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications.
Harada T; Ohguchi H; Grondin Y; Kikuchi S; Sagawa M; Tai YT; Mazitschek R; Hideshima T; Anderson KC
Leukemia; 2017 Dec; 31(12):2670-2677. PubMed ID: 28490812
[TBL] [Abstract][Full Text] [Related]
16. The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
Baumann P; Junghanns C; Mandl-Weber S; Strobl S; Oduncu F; Schmidmaier R
Br J Haematol; 2012 Mar; 156(5):633-42. PubMed ID: 22211565
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy.
Kaufman JL; Fabre C; Lonial S; Richardson PG
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):370-6. PubMed ID: 23787122
[TBL] [Abstract][Full Text] [Related]
18. Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects.
Ru J; Wang Y; Li Z; Wang J; Ren C; Zhang J
Eur J Med Chem; 2023 Dec; 261():115800. PubMed ID: 37708798
[TBL] [Abstract][Full Text] [Related]
19. Panobinostat for the treatment of multiple myeloma.
Neri P; Bahlis NJ; Lonial S
Expert Opin Investig Drugs; 2012 May; 21(5):733-47. PubMed ID: 22404247
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors in cancer therapy.
Lane AA; Chabner BA
J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
